Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of “Hold” from Analysts

Biogen Inc. (NASDAQ:BIIB) has been given a consensus recommendation of “Hold” by the twenty-eight brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and twelve have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $205.3077.

BIIB has been the subject of several analyst reports. Mizuho boosted their target price on shares of Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Tudor Pickering set a $201.00 price target on shares of Biogen in a research report on Monday, February 9th. Wedbush lifted their price objective on shares of Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a research note on Monday, February 9th. Guggenheim lifted their price objective on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, TD Cowen upped their target price on Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research note on Monday, February 9th.

Insider Activity

In other news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.18% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Norges Bank bought a new position in shares of Biogen in the fourth quarter worth about $464,408,000. Boston Partners bought a new stake in shares of Biogen during the 4th quarter valued at approximately $302,815,000. Fred Alger Management LLC grew its holdings in shares of Biogen by 39,074.8% during the 4th quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after purchasing an additional 796,735 shares during the last quarter. Employees Provident Fund Board acquired a new position in Biogen during the 4th quarter worth approximately $123,931,000. Finally, Orion Porfolio Solutions LLC increased its position in Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after purchasing an additional 509,809 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

BIIB opened at $183.64 on Tuesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen has a 52-week low of $110.04 and a 52-week high of $202.41. The firm has a market cap of $26.95 billion, a P/E ratio of 20.84, a price-to-earnings-growth ratio of 1.44 and a beta of 0.15. The business’s fifty day moving average is $184.02 and its 200-day moving average is $169.17.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the firm earned $3.44 earnings per share. Biogen’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Sell-side analysts expect that Biogen will post 15.83 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.